Incretin mimetics (IMs)—a new generation of anti-obesity medications, such as long-acting glucagon-like peptide 1 (GLP-1) receptor agonists—can result in an average of 15%–20% maximum weight loss, improvements in cardiometabolic risk factors, and prevention of secondary cardiovascular events.1,2 However, adverse events, including nausea, vomiting, and diarrhea, often lead to medication discontinuation.3 Safety issues associated with continued use, such as loss of skeletal muscle mass among older adults and incidence of pancreatitis,4,5 are also a concern. This evidence concerns the gene GCG and obesity disorder.